From nationwide Danish registries, we identified all patients with incident prostate adenocarcinoma from 1998 to 2011 and retrieved data on tumor and patient characteristics, drug use, and primary treatment.
We defined post diagnosis use (two or more prescriptions) of statins as a time-varying covariate with 1-year lag. Cox proportional hazards regression models used to compute hazard ratios (HRs) for prostate cancer-specific mortality and all-cause mortality through 2013 associated with post diagnosis statin use. In secondary and sensitivity analyses, we assessed statin use within exposure periods of 1 year or 5 years after prostate cancer diagnosis and evaluated the influence of pre diagnosis statin use.
Results: Among 31,790 patients, 7,365 died of prostate cancer and 11,811 died from other causes during a median follow-up of 2.8 years (interquartile range, 1.3 to 5.1 years) from 1 year after diagnosis.
Signe Benzon Larsen1, Christian Dehlendorff1, Charlotte Skriver1, Susanne Oksbjerg Dalton1, Christina Gade Jespersen4,5, Michael Borre5, Klaus Brasso2, Mette Nørgaard5, Christoffer Johansen1,2, Henrik Toft Sørensen5, Jesper Hallas6, Søren Friis1,3,5.
1. Danish Cancer Society Research Center
2. Copenhagen University Hospital;
3. University of Copenhagen, Copenhagen
4. Viborg Hospital, Viborg;
5. Aarhus University Hospital, Aarhus
6. University of Southern Denmark, Odense, Denmark
Pub Med Article
Watch: Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?- Lorelei Mucci
Associations Between Statin Use and Progression in Men with Prostate Cancer Treated with Primary Androgen Deprivation Therapy
The Impact of Statin Use on the Efficacy of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer